ICCCHealthcare · Biotechnology

ICCC Stock Forecast: ImmuCell Corp. Price Predictions for 2026-2027

Last close, 18 Sept 2026

$9.95

−0.30% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 19 Sept 2026 — among the strongest tenth.

Market cap

$87.3M

Ticker Nerd rank

94 / 100

Median analyst target

—

Analysts covering

Revenue$7.2M+11.5% y/y

Operating income$1.9M

Net income$1.8M

Free cash flow$2.3M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+1.0%

+1.9%

YTD

+61.8%

+75.8%

From 52W high

−15.1%

From 52W low

+118.2%

$12

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

ICCC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ImmuCell Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026

94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

Quality

Volatility

Momentum

Issuance

Size

Value

Growth

Revisions

Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ICCC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ICCC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
13 July 2020	Aegis Capital	Initiates	Buy	$14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ICCC appears on the weeks it earns a place.

Performance

ICCC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, ImmuCell Corp. returned +75.8% against +16.3% for the S&P 500, dividends included.

ICCC vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ICCC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

ImmuCell Corp. (ICCC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 137.3×
Price / sales: 2.8×
Price / book: 2.8×
EV / EBITDA: 12.9×

Growth & margins

Revenue growth (YoY): 11.5%
Earnings growth (YoY): 265.6%
Gross margin: 33.9%
Operating margin: 26.9%
Net margin: 2.6%

Returns & dividend

Return on equity: 2.6%
Return on assets: 6.2%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ImmuCell Corp. (ICCC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

ImmuCell Corp. has a market value of $87.3M and an enterprise value of $90.9M.
Revenue in the twelve months to 30 June 2026: $30.7M. The latest quarter grew 11.5% year on year.
Net income over the same four quarters: $787K, a 2.6% net margin.
Diluted earnings per share, trailing twelve months: $0.08.
Free cash flow in the twelve months to 30 June 2026: $4.2M.
Shares outstanding: 9.1M.
Trailing P/E: 137.3×; forward P/E: −87.4× — the forward figure prices analyst consensus estimates, not reported earnings.
ImmuCell Corp. employs 73 people — $420K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

ICCC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
ICCCImmuCell Corp.	$87.3M	94
RLYBRallybio Corp.	$90.8M	59
ACETAdicet Bio, Inc.	$87.9M	43
ANIXAnixa Biosciences, Inc.	$92.9M	69
PTHSPelthos Therapeutics, Inc.	$86.7M	19
NTHINeOnc Technologies Holdings, Inc.	$93.9M	20
NRXSNeurAxis, Inc.	$94.2M	60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ImmuCell Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ICCC news & analysis

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2

Zacks Investment Research · 27 Aug 2026negative

ImmuCell Corp.'s stock fell 8.8% after reporting Q2 results in which sales rose 11.5% year over year but margins contracted. A $2-million legal settlement boosted profit, and the company is planning a capacity expansion.

Why it matters — ICCC watchers would care because the revenue growth is offset by margin contraction, and the profit was aided by a one-time legal settlement while the company prepares for a capacity expansion.

ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

This item is the transcript of ImmuCell Corporation's Q2 2026 earnings call, published by Seeking Alpha. It presents the company's second-quarter earnings discussion in its own words.

Why it matters — An ICCC watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly financial results and management commentary.

ImmuCell Q2 Earnings Call Highlights

MarketBeat · 14 Aug 2026positive

ImmuCell reported higher second-quarter sales and earnings, driven by increased domestic demand for its calf scours prevention products. The company also outlined plans to invest roughly $8 million to more than triple manufacturing capacity by the end of 2027.

Why it matters — For an ImmuCell watcher, the reported sales and earnings gains along with the announced capacity expansion signal ongoing product demand and preparation for greater manufacturing output in the coming years.

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

GlobeNewsWire · 13 Aug 2026neutral

ImmuCell Corporation, an animal health biologics company, announced its unaudited financial results for the quarter ended June 30, 2026. The announcement was made on August 13, 2026, via GlobeNewswire.

Why it matters — ICCC watchers would care because this is the company's latest quarterly financial disclosure, providing current insight into its performance.

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

GlobeNewsWire · 6 Aug 2026neutral

ImmuCell announced it will report unaudited financial results for the quarter ended June 30, 2026, after the market closes on August 13, 2026, and will host a conference call and webcast on August 14, 2026, at 9:00 AM ET to review the results.

Why it matters — This notice gives ImmuCell watchers the date and time for the company's upcoming quarterly earnings report and management's review of its recent performance.

FAQ

Frequently asked questions about ICCC stock

How does Ticker Nerd's model rank ICCC?

As at 19 Sept 2026, ImmuCell Corp. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).

What is the ICCC stock forecast for 2030?

No analyst covering ImmuCell Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICCC are extrapolating price history, which says nothing about the business.

How has ICCC stock performed over the past year?

ImmuCell Corp. returned +75.8% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ImmuCell Corp. do?

What is the latest news on ICCC?

The most recent item we track (Zacks Investment Research, 27 Aug 2026): "ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2". ImmuCell Corp.'s stock fell 8.8% after reporting Q2 results in which sales rose 11.5% year over year but margins contracted. A $2-million legal settlement boosted profit, and the company is planning a capacity expansion.

Company

About ImmuCell Corp.

ImmuCell Corporation is an animal health biologics company focused on products that support calf health and cattle productivity. The company develops, manufactures, and markets the First Defense product line, which is designed to help protect newborn calves against scours, a major cause of early-life illness in dairy and beef operations. ImmuCell also offers mastitis-related diagnostic products, including cow-side testing tools used to identify elevated somatic cell counts and help detect mastitis in dairy herds. Its current business is centered on practical, science-based solutions for livestock producers in the dairy and beef industries, with an emphasis on improving animal survivability, health, and day-to-day herd management. Headquartered in Portland, Maine, ImmuCell serves a specialized niche in the animal-health market through biologics, immunological products, and diagnostic assays.

CEO Mr. Paul F. Olivier Te Boekhorst · 73 employees · United States · https://immucell.com